Stockreport

Kymera Therapeutics To Present Pre-clinical Data At The EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development And Prevented Rheumatoid Arthritis [TheStreet.com]

Kymera Therapeutics, Inc.  (KYMR) 
PDF WATERTOWN, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degra [Read more]